Poloxamer composition free of long-term circulating substances, method for producing the same, and use thereof
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- LIFERAFT BIOSCIENCES INC
- Filing Date
- 2023-01-11
- Publication Date
- 2026-06-22
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Commercial poloxamer formulations contain a heterogeneous mixture of molecules with varying sizes and structures, leading to unpredictable bioactivity and potential undesirable effects due to the presence of long-circulating substances, which complicate their use in medical applications.
Development of long-cycle-free (LCMF) poloxamer 188 formulations with controlled molecular composition and reduced polydispersity, achieved through supercritical fluid extraction methods to remove low and high molecular weight impurities, ensuring all components have a circulating half-life five times or less than the main component, and increased hydrophilicity.
LCMF poloxamer 188 exhibits predictable bioactivity, reduced retention time, and improved safety by eliminating long-circulating substances, making it suitable for medical treatments such as heart failure, myocardial infarction, and blood transfusions.
Smart Images

Figure 0007877236000020 
Figure 0007877236000021 
Figure 0007877236000022
Abstract
Citation Information
Patent Citations
JP1994506258A
JP2014506234A